What is 3SBio?
Founded in 1993, 3SBio operates as a fully-integrated biotechnology enterprise with a diversified portfolio spanning critical therapeutic areas including oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology. Headquartered in Liaoning, China, the company leverages a robust research and development infrastructure to maintain its competitive edge. By integrating manufacturing, marketing, and clinical research, 3SBio has successfully navigated the complexities of the Chinese healthcare market, positioning itself as a primary provider of specialized medical solutions. Its business model is characterized by a deep commitment to addressing unmet medical needs through high-barrier-to-entry biological products, ensuring long-term sustainability in a rapidly evolving regulatory environment.
How much funding has 3SBio raised?
3SBio has raised a total of $712M across 1 funding round:
Stock Offering
$712M
Stock Issuance/Offering (2015): $712M, investors not publicly disclosed
Key Investors in 3SBio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for 3SBio?
With the recent capital injection, 3SBio is well-positioned to accelerate its strategic initiatives, particularly in the scaling of its oncology and nephrology franchises. The company is expected to prioritize the expansion of its clinical pipeline and the optimization of its manufacturing capabilities to meet increasing domestic demand. Furthermore, the firm will likely focus on strengthening its market position through potential strategic partnerships and the continued integration of advanced biotechnological processes. As it moves into this next phase of enterprise-level growth, 3SBio remains focused on enhancing its operational efficiency and maintaining its leadership in the Chinese biopharmaceutical sector, ensuring that its research-driven approach continues to yield significant clinical and commercial outcomes.
See full 3SBio company page
